Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564343PMC
http://dx.doi.org/10.2215/CJN.0000000000000258DOI Listing

Publication Analysis

Top Keywords

reducing kidney
4
kidney disease
4
disease burden
4
burden type
4
type diabetes
4
diabetes sglt2
4
sglt2 inhibitors
4
inhibitors shifting
4
shifting goalposts
4
goalposts upstream
4

Similar Publications

A pediatric-onset case of chronic kidney disease caused by a novel sporadic variant and literature review.

Turk J Pediatr

September 2025

West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan, China.

Background: The α-actinin-4 (ACTN4) gene encodes an actin-binding protein, which plays a crucial role in maintaining the structure and function of podocytes. Previous studies have confirmed that ACTN4 mutations can lead to focal segmental glomerulosclerosis-1 (FSGS1), a rare disease primarily manifesting in adolescence or adulthood, characterized by mild to moderate proteinuria, with some cases progressing slowly to end-stage renal disease.

Case Presentation: We report a 12.

View Article and Find Full Text PDF

Kidney stone disease increases the risk of cardiovascular events.

PLoS One

September 2025

Department of Cardiology, Fuzhou University Affiliated Provincial Hospital, Fujian Provincial Hospital, Fuzhou, Fujian, China.

Introduction: Kidney stone disease is associated with numerous cardiovascular risk factors. However, the findings across studies are non-uniformly consistent, and the control of confounding variables remains suboptimal. This study aimed to investigate the association between kidney stone and cardiovascular disease.

View Article and Find Full Text PDF

As plasma biomarkers like p-tau217 move towards clinical use in Alzheimer's disease (AD), it is important to understand how kidney function may influence their accuracy. Even mild chronic kidney disease (CKD) can alter biomarker levels, potentially impacting test performance. While accounting for renal function may improve specificity, it could reduce sensitivity without greatly changing overall diagnostic accuracy.

View Article and Find Full Text PDF

Role of Systemic Glucocorticoids in Reducing IgA and Galactose-Deficient IgA1 Levels in IgA Nephropathy.

Clin J Am Soc Nephrol

September 2025

Kidney Division, Peking University First Hospital, Peking University Institute of Nephrology; Key Laboratory of Kidney Disease, Ministry of Health of China; Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education, China.

Background: The Therapeutic Effects of Steroids in IgA Nephropathy Global (TESTING) trial demonstrated that glucocorticoid therapy reduced proteinuria and improved kidney outcomes in patients with Immunoglobulin A Nephropathy (IgAN). Galactose-deficient IgA1 (Gd-IgA1) plays a central role in IgAN pathogenesis by promoting immune complex formation. However, the effects of glucocorticoid on pathogenic IgA levels remain unclear.

View Article and Find Full Text PDF

Importance: Patients with kidney failure (KF) receiving long-term dialysis have increased incidence of atrial fibrillation (AF). Patients with KF and AF have increased risk of stroke, death, and bleeding compared with age-matched cohorts. In KF, the use of oral anticoagulants (OACs) increases hemorrhage risk, offsetting potential benefits and making left atrial appendage occlusion (LAAO) a potentially promising solution for risk reduction in AF.

View Article and Find Full Text PDF